Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma
Immunocore Limited, a leading T cell receptor biotechnology company, and Pulse Infoframe, Inc. (Pulse), a data aggregation and analytics company, today announce plans to support the first global patient registry in uveal melanoma (UM), a rare and aggressive form of melanoma, which affects the eye, typically has a poor prognosis and for which there is no currently accepted optimal management or treatment.1 The insights gained through the academic registry will provide a more comprehensive understanding of the disease and may help to shape the way future research is conducted.
The registry will include institutions from across the US, UK and Australia, and is currently being developed by leaders in the field of uveal melanoma, including:
- Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, Columbia University, US
- Joseph Sacco, PhD, Clinical Senior Lecturer at the University of Liverpool and Honorary Consultant in Medical Oncology at Clatterbridge Cancer Centre, UK
- Anthony Joshua, MBBS, PhD, Director of Cancer Services at St Vincent's Hospital and conjoint Associate Professor with the University of New South Wales, Australia
“The rarity of uveal melanoma makes it difficult to collect the data needed to better understand how the disease manifests and evolves, and who is likely to respond to treatment and why,” said Dr. Carvajal. “For the first time we’ll have the opportunity to prospectively collect and analyse global real-world data, including patient-reported outcomes. This will help to guide medical research, innovative trial design and recruitment, potentially paving the way for accelerated treatment advances.”
Research generated from the registry will examine risk factors, genetics, epidemiology, treatment cost-effectiveness and real-world outcomes from a database of patients with uveal melanoma. The goal is to create a benchmark framework, or ecosystem, for collecting and assessing clinical outcomes, as well as providing necessary data for future genetic, sub-phenotype and biomarker research.
“We’re excited to be working with the research community to address the need for a more comprehensive understanding of uveal melanoma,” said Mohammed Dar, MD, Head of Clinical Development and Chief Medical Officer at Immunocore. “We believe that this registry will provide critical insight that may help to advance the development of future treatments, including clinical and genetic information about potential subsets of people living with this devastating disease.”
Enrolment into the registry is expected to begin in August at five sites in the US, three sites in the UK, and three sites in Australia.
“At Pulse, we strive to support the entire ecosystem that researchers, clinicians and patients require to generate the real-world evidence necessary to advance clinical outcomes, support patient advocacy and promote disease awareness,” said Femida Gwadry-Sridhar, RPh, PhD, CEO and Founder at Pulse. “We are pleased to partner with Immunocore and key academic leaders on this patient registry, which will provide a detailed look into uveal melanoma from a global perspective.”
About Uveal Melanoma
Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye, typically has a poor prognosis and for which there is no currently accepted optimal management or treatment.1 Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases/year in the US).1,2,3,4 Up to 50% of people with uveal melanoma will eventually develop metastatic disease.1 When the cancer spreads beyond the eye, only approximately 40% of patients will survive for one year.1
Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies that have the potential to transform patients’ lives. The Company’s primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken, PA and Rockville, MD, US. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.
About Pulse Infoframe, Inc. (Pulse)
Focusing on rare disease and cancer, Pulse is a new style informatics company delivering real-world insights and precision knowledge through dynamic analytics and data visualization to accelerate time-to-value. Pulse aggregates data, including patient reported outcomes, from multiple sources making it available to researchers and relevant stakeholders and offers numerous benefits including dramatically improved collaboration, informing decision making and leading to advances in treatment. Pulse is headquartered in Canada, with offices in the United States, and the United Kingdom. For more information, please visit www.pulseinfoframe.com.
1 Carvajal, RD, Schwartz, GK, Tezel, T, et al., 2017. Metastatic disease from uveal melanoma: treatment options and future prospects. British Journal of Ophthalmology, 101(1), 38-44.
2 Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31(8):724-743.
3 Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6(7):1230-1244.
4 About ocular melanoma. Ocular Melanoma Foundation website. www.ocularmelanoma.org/about-om.htm. Accessed May 2019.
Louise Conlon, External Affairs and Brand Communications Manager
T: +44 (0) 1235 438600
Follow on Twitter: @Immunocore
Syneos Health Communications (Tebentafusp/IMCgp100)
T: +973 477 1814
Tamara Howard, PhD, Vice President of Patient Advocacy
T: +888 787 8573
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
nCipher Introduces Cloud-first Architecture, Bringing Security and Control to Public and Private Clouds29.1.2020 11:00:00 EET | Press release
nCipher Security, an Entrust Datacard company and provider of trust, integrity and control for business critical information and applications, announces two new additions to its nShield® hardware security module (HSM) portfolio – nShield Web Services Option Pack and nShield Container Option Pack – that make it simpler to deploy applications in the cloud and bring greater security and control to public and private clouds. nShield Web Services Option Pack simplifies deployment for cloud-first data centres. nShield Web Services Option Pack provides a REST API between applications requiring cryptographic key and data protection services and nShield HSMs, enabling seamless application deployment underpinned by high-assurance nShield HSMs, which can dynamically scale to meet the needs of cloud-ready data centers. Customers can also use their own load balancing appliances to handle the HSM workload, simplifying the HSM deployment and configuration, and ensuring the best utilization of their H
Denenchofufutaba Gakuen, NTT Group Start a Joint Study to Create Smart Campus Solutions29.1.2020 10:32:00 EET | Press release
NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT DATA Corporation, NTT COMWARE Corporation, NTT Communications Corporation, NTT Ltd., Nippon Telegraph and Telephone East Corporation (Hereinafter, NTT East)) will begin a joint study with Denenchofufutaba Gakuen in order to develop smart campus solutions that will provide safety and security at schools. NTT Group implements technology of public safety solution that will draw on the proven implementation for the City of Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005916/en/ Solution Overview (Graphic: Business Wire) 1. Background In recent years, there have been several crimes and incidents involving students in school facilities, and resulting in requests to improve safety measures in addition to crime prevention activities by national and local governments. Furthermore, with the introduction of new educational guidelines, the w
Panasonic Develops High-Power Blue WBC Technology to Revolutionize DDL Applications on Microfabrication29.1.2020 09:11:00 EET | Press release
On January 29, 2020, Panasonic Corporation announced it has succeeded in demonstrating the world's highest brightness blue laser. This has been achieved by using the wavelength beam combining (WBC) technology  on a direct diode laser (DDL) to produce a high quality output beam . With this technology, power scaling is enabled while maintaining the beam quality by simply increasing the number of laser sources. This demonstration opens the door to laser intensities that could be two orders of magnitude higher than conventional blue laser systems. This technology will contribute to the emerging microfabrication processes, whose demand is expected to grow in industrial applications, such as in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005907/en/ Wavelength Beam Combining (WBC) technology (Graphic: Business Wire) The automotive industry is moving towards “electrification” and “miniaturizat
NTT Group to Launch Asia's First Smart City Proof of Concept Collaborating with Cyberview and Allo in Malaysia29.1.2020 09:00:00 EET | Press release
As part of the Japanese Ministry of Internal Affairs and Communications’ FY 2019 project "Research on Smart City Model for Solving Social Problems in Malaysia", based on the smart city initiatives which has been started with the City of Las Vegas, United States, NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT Communications Corporation, NTT Ltd., InfoCom Research, Inc., NTT DATA Corporation, NTT COMWARE Corporation) will conduct Asia's one of the first Smart City Proof of Concept (PoC) in the Cyberjaya area of Malaysia from February 2020, in cooperation with local stakeholders. Through this PoC, NTT Group aims to establish a sustainable business model while verifying the possibility of solving social issues in Asia, utilizing the technologies and know-how accumulated in the smart city field in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005904/en/ (Graphic: Business W
Kioxia Appoints Masaki Momodomi as Chief Technology Officer29.1.2020 07:00:00 EET | Press release
Kioxia Holdings Corporation today announced the appointment of Masaki Momodomi as Chief Technology Officer (CTO) of Kioxia, effective immediately. Mr. Momodomi fills the role of Former CTO Nobuo Hayasaka, who has been appointed as President and Chief Executive Officer (CEO) of Kioxia. Mr. Momodomi has an accomplished background in the memory industry, bringing over 40 years of experience across roles at Kioxia, Toshiba Memory and Toshiba Corporation. Following Toshiba Memory’s separation from Toshiba Corporation, Mr. Momodomi was named director of Toshiba Memory, now Kioxia’s Institute of Memory Technology Research and Development. Previously, he served as director of Toshiba Corporation’s Center of Semiconductor Research and Development. A pioneer in the memory field, in 1987, Mr. Momodomi co-authored a dissertation on Toshiba’s invention of NAND Flash memory, playing a vital role in the exponential growth of the now ubiquitous technology. Mr. Momodomi graduated from Kyushu University
Kioxia Appoints Nobuo Hayasaka as President and CEO29.1.2020 07:00:00 EET | Press release
Kioxia Holdings Corporation today announced that the Board of Directors has appointed Nobuo Hayasaka as President and CEO of Kioxia, effective immediately. Dr. Hayasaka has served as Acting President and CEO since July 12, 2019, during Former President and CEO Yasuo Naruke’s medical leave of absence. Dr. Naruke notified the company’s Board of Directors of his desire to step down as President, CEO and member of the board as he continues to focus on his health. “Dr. Naruke has been an outstanding leader for our company over many years, and we thank him for the invaluable contribution he has made to shaping us into the company we are today.” said Stacy J. Smith, Executive Chairman of Kioxia. “This year presents an exciting opportunity for Kioxia, and President Hayasaka has the skills, experience and the full backing of our Board of Directors, management and employees as we move toward a new era of memory. I look forward to working closely with President Hayasaka and the rest of the execut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom